Connect with us

Israel News

Could Israel’s New Immunotherapy Treatment Become a Possible Cure for Cancer?



Immunovative lab technicians at work in Jerusalem. (Photo: courtesy)

Ten years ago, Dr. Michael Har-Noy, founder and CEO of a Jerusalem-based startup developing an immunotherapy treatment that could potentially cure cancer, lamented that the fight against the dreaded disease “is a battle we are losing.” Today, Har-Noy’s company is getting closer to turning the tide.

n the past decade, Immunovative Therapies has conducted dozens of clinical trials, opened branches in California, Arizona and Thailand, and raised $35 million.

But the biggest boost came from the publicity surrounding immunotherapy pioneer Jim Allison, who won this year’s Nobel Prize in chemistry.

Ten years ago, “We couldn’t get a venture capitalist to open a business plan if they saw the words ‘immunotherapy.’ They’d say, ‘That doesn’t work in cancer,’” Har-Noy tells ISRAEL21c.

Following Allison’s work that proved immunotherapy’s efficacy, “anyone with ‘immune’ in their name is now able to raise funds,” Har-Noy says.

Indeed, consulting firm Transparency Market Research predicts that the global market value of cancer immunotherapy drugs will reach $124 billion by 2024.

Is the excitement warranted? After all, science is filled with promising approaches that don’t pan out in the end. In the case of immunotherapy, the answer seems to be yes. Immunotherapy is the only current mode of treatment that could actually cure cancer, Har-Noy says.

Unlike chemotherapy, which as its name implies uses noxious chemicals to kill cancer cells (along with a lot of healthy ones), immunotherapy enlists the body’s own immune system to do the heavy lifting.

Moreover, while chemotherapy is often effective, it’s not always permanent. If even a single cancer cell survives, it can begin to replicate and start the process of tumor-building all over again.

The goal with immunotherapy is to “train” the immune system to hunt down and destroy every last cancer cell, including those in metastatic tumors resistant to chemotherapy.

However, today’s immunotherapy drugs “only work in 20 percent of patients,” Har-Noy says. “And they’re still toxic. That means 80 percent of patients get no clinical benefit but they get the toxicity.”

Nor does immunotherapy work in some cancers – including colorectal cancer, which is among the three biggest killers worldwide. That’s one reason Immunovative is focusing first on tackling bowel, colon and liver cancers.

There are relatively few drugs to treat colorectal cancer and “the ones that exist are relatively ineffective, only extending life by a matter of months, not years,” explains Har-Noy.

Immune cells from a healthy donor

The Immunovative process starts by collecting immune cells from a normal, healthy donor. There’s no need to “match” the donor cells to the recipient.

Immunovative technicians purify and culture the donor’s healthy T-cells in a bioreactor, which causes them to multiply and activate without any genetic engineering or manipulation. Immunovation has a patent on the new immune cells, which it calls AlloStim.

The AlloStim cells are next injected into the cancer patient. While the body will reject these alien cells, subsequent injections lead the patient to develop immunity to the foreign cells and to create more of a particular type of immune cell called “memory Th1,” which is normally suppressed in cancer patients.

he final step is injection of AlloStim intravenously. The body’s new abundance of Th1 cells rush to the tumors and, in conjunction with existing “natural killer” cells, begin decimating the tumors. As more AlloStim is injected, the body creates its own tumor-specific Th1 immune cells, essentially vaccinating itself against the cancer.

The AlloStim process also “teaches” the immune system to seek out similar cancerous tumors throughout the body. This means it will spring into action any time it detects the same type of cance, even years after treatment.

One donor can potentially produce enough cells to treat up to 1,000 patients, making the resulting drug affordable even to economically disadvantaged patients.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement --


Daily Newsletter

Get all the breaking news delivered right to your inbox as it happens

Sign Up Now!


At Your Doorstep

No more hassles running to the newsstand, as each week for a month, you can now sit back, relax and enjoy the Jewish Voice in the comfort of your own home!